首页 › 基金 › JOHNSON & JOHNSON › PTGX
JOHNSON & JOHNSON 对 PTGX 的持仓历史
PROTAGONIST THERAPEUTICS INC · 医疗保健
JOHNSON & JOHNSON 在 Q3 2026 的 13F 申报中披露持有 PTGX(PROTAGONIST THERAPEUTICS INC)2,449,183 股,市值约 US$345.1M,约占其申报组合的 45.30%,在其申报持仓中市值排名第 1 位。 JOHNSON & JOHNSON 最近 13 个申报季度中有 13 个季度披露了 PTGX 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
JOHNSON & JOHNSON 对 PTGX 的持仓演变
JOHNSON & JOHNSON 于 Q3 2023 首次披露 PTGX 持仓:2,449,183 股(约 US$40.9M)。 该持仓在 Q3 2026 达到峰值 2,449,183 股,市值约 US$345.1M。 在 13 次申报中,JOHNSON & JOHNSON 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 2,449,183 股、市值约 US$345.1M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 2.45M | $40.85M | 新进 |
| Q4 2023 | 2.45M | $56.16M | 持有 |
| Q1 2024 | 2.45M | $70.85M | 持有 |
| Q2 2024 | 2.45M | $84.86M | 持有 |
| Q3 2024 | 2.45M | $110.21M | 持有 |
| Q4 2024 | 2.45M | $94.54M | 持有 |
| Q1 2025 | 2.45M | $118.44M | 持有 |
| Q2 2025 | 2.45M | $136.40M | 持有 |
| Q3 2025 | 2.45M | $162.70M | 持有 |
| Q4 2025 | 2.45M | $213.91M | 持有 |
| Q1 2026 | 2.45M | $258.14M | 持有 |
| Q2 2026 | 2.45M | $300.22M | 持有 |
| Q3 2026 | 2.45M | $345.07M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 PTGX 与 13F 数据
PTGX(PROTAGONIST THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 50 只申报持有 PTGX,申报仓位最大的包括:法拉龙资本管理 (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 PTGX 的基金
- 法拉龙资本管理 6.35M 股 · $778.25M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.35M 股 · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M 股 · $620.40M · Q2 2026
- Woodline Partners LP 1.41M 股 · $173.35M · Q2 2026
- PERCEPTIVE ADVISORS LLC 981.88K 股 · $120.36M · Q2 2026
- ADAR1 Capital Management, LLC 960.86K 股 · $117.78M · Q2 2026
- Hood River Capital Management LLC 882.74K 股 · $108.21M · Q2 2026
- 683 Capital Management, LLC 290.00K 股 · $35.55M · Q2 2026
- NEXTBio Capital Management LP 219.33K 股 · $30.90M · Q3 2026
- Eagle Health Investments LP 248.32K 股 · $30.44M · Q2 2026
更多关于 JOHNSON & JOHNSON
常见问题
How long has JOHNSON & JOHNSON held PTGX?
JOHNSON & JOHNSON has disclosed PTGX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is JOHNSON & JOHNSON's current position in PTGX?
As of Q3 2026, JOHNSON & JOHNSON holds 2.45M shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $345.07M, representing 45.30% of its reported portfolio and ranking #1.
Has JOHNSON & JOHNSON been buying or selling PTGX?
In the latest 13F filing (Q3 2026), JOHNSON & JOHNSON held unchanged its position in PTGX. The position peaked in Q3 2026 at 2.45M shares.
Which other funds hold PTGX?
Other major institutional holders of PTGX include 法拉龙资本管理, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.